Despite securing a much-needed $5 million lifeline from an equity offering this week, HCW Biologics is continuing to warn ...

HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and ...

HCW Biologics Inc. (the "Company” or "HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on ...

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading ... The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for ...

ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta ...

BlueSphere Bio, a clinical stage drug development company focused on novel T cell based therapies, today announced the appointment of Alan Korman, Ph.D., as Chief Scientific Officer. Dr. Korman brings ...

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

ROCKVILLE, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage ...

Creative Biolabs upgrades its therapeutic antibody and protein development platform, with enhanced capabilities in endotoxin ...

Discover how Bruker is advancing live single-cell functional analysis, helping to accelerate breakthroughs in immunology and ...

ORKA-001, targeting IL-23p19, Phase 1 trial dosing complete, with data expected in 3Q 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout expected in 2H 2026 that will provide ...